Aditxt CEO presents at investor event; updates on Evofem close, Pearsanta commercialization, crypto strategy

Aditxt, Inc.

CEO Amro Albanna presented at Wall Street Reporter's Next Super Stock livestream on July 8, 2025, discussing business model as 'publicly owned innovation accelerator'.
Pearsanta validation ongoing; expects to commercialize prostate cancer and endometriosis tests by Q1 2026.
Evofem acquisition (women's health) expected to close by end of September 2025, subject to financing, as anchor for Adifem.
Announced Bitcoin/crypto treasury strategy to broaden shareholder base; market cap ~$5M.
Adimune plans to file for human trials Q4 2025/Q1 2026 for stiff person syndrome, type 1 diabetes, psoriasis.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.